BEAUFIELD HOMES LIMITED

Financial Health Score: D+ (Vulnerable)

Beaufield Homes Limited is currently in a fragile state of recovery. While the business has recently returned to positive net assets after a period of technical insolvency, it suffers from acute short-term liquidity constraints and has undergone a dramatic contraction from its historical financial peak.

1. Key Vital Signs

• Liquidity (Blood Pressure): Critically Low. The company has current assets of £10,803 against current liabilities of £20,780, resulting in net current liabilities of £9,977. This gives a current ratio of roughly 0.52:1. In medical terms, the business has severely restricted cash flow, meaning it cannot cover its immediate short-term debts from its liquid assets without external intervention.
• Solvency (Heartbeat): Weak but Present. Net assets have recovered to £2,799 after falling into negative territory (-£12,738) in 2024. The "heartbeat" of the business is present, but the margin for error is incredibly slim. Total liabilities (£63,004) still consume roughly 96% of total assets (£65,803).
• Asset Base (Muscle Mass): Significantly Atrophied. The business has experienced dramatic muscle wastage over the last five years. From a peak of £9.24M in total assets in 2019, the balance sheet has shrunk to just £65,803. The remaining "muscle" consists primarily of £55,000 in fixed assets, leaving very little operational flexibility.
• Debt Burden (Cholesterol): High Buildup. Long-term creditors fell from £123,191 to £42,224, which is a positive sign of debt clearance. However, the short-term creditor pile has grown, suggesting that debts are simply shifting from long-term to short-term, increasing immediate payment pressure.

2. Diagnosis

Severe Atrophy with Acute Short-Term Liquidity Deficiency

Looking at the patient's medical history, Beaufield Homes Limited was once a robust, multi-million-pound enterprise (peaking at nearly £6M in net assets in 2018/2019). Between 2019 and 2021, the business underwent what appears to be a major surgical amputation—likely a distribution of property assets or a sale of major holdings to its parent company or major shareholder, Finfitz Holdings Limited.

Since that major event, the company has been operating as a micro-entity with a skeletal structure (only 2 employees). The immediate diagnosis is a business suffering from a severe working capital deficit. Because current liabilities exceed current assets, the company is technically insolvent on a short-term basis. It is surviving day-to-day only because of the implied life support provided by its People with Significant Control (Finfitz Holdings and Patrick Jeremy O'Brien, who hold over 75% control), who are likely allowing these short-term debts to remain outstanding without calling for immediate repayment.

The reduction of long-term debt by roughly £81,000 this year is a healthy sign of debt restructuring, but the patient is still heavily reliant on creditor forbearance to keep its doors open.

3. Recommendations

To nurse this patient back to stable health and avoid a relapse into insolvency, the following financial prescriptions are recommended:

• Equity Transfusion (Capital Injection): The controlling shareholders (Finfitz Holdings / Patrick O'Brien) should formally inject fresh equity or convert existing director/parent company loans into long-term capital. This will boost net current assets and cure the short-term insolvency, providing a healthy cash flow buffer.
• Debt Restructuring (Arterial Clearance): Negotiate with short-term creditors to extend payment terms. Moving a portion of the £20,780 short-term debt to long-term liabilities will immediately improve the current ratio and ease the immediate cash flow blockage.
• Asset Realization Strategy: With £55,000 tied up in fixed assets, the directors must assess whether these assets are generating a return. If they are dormant or underutilized, selling them to boost current assets (cash) would drastically improve the business's immediate liquidity.
• Strategic Check-Up: Given the drastic reduction in scale from a £9M operation to a £65k micro-entity, the directors need a clear strategic review. Is the intention to wind the company down, or is it being used as a holding vehicle for the next property development? The current financial structure is too thin to sustain any unexpected shocks or operational delays.